Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
interferon alfa-2b · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1: interferon alfa-2b (dose 1) | EXPERIMENTAL | continuous subcutaneous infusion for 48 weeks |
| Group 2: interferon alfa-2b (dose 2) | EXPERIMENTAL | continuous subcutaneous infusion for 48 weeks |
| Group 3: interferon alfa-2b (dose 3) | EXPERIMENTAL | continuous subcutaneous infusion for 48 weeks |
| Group 4: peginterferon alfa-2b (1.5 μg/kg) | ACTIVE_COMPARATOR | subcutaneous weekly for 48 weeks |
| Name | Type | Description |
|---|---|---|
| interferon alfa-2b | DRUG | subcutaneous continuous infusion at one of three doses for 48 weeks |
| peginterferon alfa-2b | DRUG | 1.5 μg/kg subcutaneous weekly for 48 weeks |
| ribavirin, USP | DRUG | All patients will receive oral ribavirin |
| external drug infusion pump | DEVICE | pump delivery system for continuous subcutaneous infusion of interferon alfa-2b |
Inclusion Criteria: * Signed patient consent form * Genotype 1 chronic HCV with detectable HCV RNA * No previous treatment for HCV infection * Hepatitis B and human immunodeficiency virus negative at screening visit * Able and willing to follow contraception requirements * Screening laboratory valu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Interferon alfa-2b is being studied for the treatment of Hepatitis C. It is an investigational therapy in Phase 2 clinical development for this indication. The drug is being evaluated in a clinical trial to compare continuous infusion of interferon with standard of care for chronic Hepatitis C.
Interferon alfa-2b is a small molecule that works by modulating the immune system to fight viral infections. It is being studied for its ability to treat Hepatitis C by enhancing the body's immune response against the virus.
Interferon alfa-2b is being developed by Medtronic plc, a company traded on the New York Stock Exchange under the ticker symbol MDT.
Interferon alfa-2b is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial for Hepatitis C has been completed.
Interferon alfa-2b has one completed clinical trial, NCT00919633, titled 'Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C.' This Phase 2 trial enrolled 116 participants in the United States.
Interferon alfa-2b is also known by other names, but specific alternative names have not been provided. It is a distinct drug being studied for Hepatitis C.